Updated on 14 January 2016
Medtronic will invest in a manufacturing facility for a next generation sensor
Singapore: Medtronic has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.
As part of the agreement, Medtronic will invest in a manufacturing facility for a next generation sensor augmented pump system with SmartGuard technology to help provide better diabetes management for the growing diabetes population in China.
In addition, Medtronic will partner with the Chengdu government to enable people with diabetes in Chengdu and the broader Sichuan province to access this new, locally produced technology with software displayed in Chinese language.
The commitment follows upon a strategic partnership agreement signed by Medtronic and the city's municipal government last September. The earlier deal commits both the Chengdu municipal government and Medtronic to expand access to proven therapies, particularly solutions for diabetes management, in China as well as other countries.
The manufacturing facility is the second Medtronic plant announced in Chengdu over the past 18 months, when the company publicized a plan to establish its first factory worldwide for portable hemodialysis equipment in August 2014.